PURPOSE: Acinetobacter baumannii is a non-fermenting aerobic gram-negative bacteria and one of the important nosocomial pathogens, especially in intensive care units (ICUs). In recent years, multidrug-resistant (MDR) isolates have been an emerging problem, with limited therapeutic options. Tigecycline is a novel antimicrobial, with its in vitro activity against most gram-positive and gram-negative pathogens. METHODS: This is a retrospective study that was conducted in a tertiary care hospital with 550 beds in Ankara, Turkey, from January 2009 to July 2010. Thirty-three patients who had carbapenem-resistant Acinetobacter spp. infections and received tigecycline alone or in combination with other antibiotics for at least 3 days were included. RESULTS: The median age of the patients was 62 (18-87) years. All of the patients were diagnosed and treated in the ICU. Clinical responses were observed in 23 patients (69.7%). Ten patients (30%) had clinical failure. There was no significant difference between ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) in terms of clinical or microbiological outcome (p > 0.05). The microbiological response rate was 50%. Superinfection was detected in 13 patients (43.3%) and Pseudomonas aeruginosa was the most frequently isolated pathogen. The 30-day overall mortality rate and attributable mortality rates were 57.6 and 24.2%, respectively. The attributable mortality rate was higher in the group in which microbiological eradication was not provided. CONCLUSIONS: Although it is approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia, emerged resistance of Acinetobacter spp. and limited therapeutic options left physicians no choice but to use tigecycline for off-label indications.
PURPOSE:Acinetobacter baumannii is a non-fermenting aerobic gram-negative bacteria and one of the important nosocomial pathogens, especially in intensive care units (ICUs). In recent years, multidrug-resistant (MDR) isolates have been an emerging problem, with limited therapeutic options. Tigecycline is a novel antimicrobial, with its in vitro activity against most gram-positive and gram-negative pathogens. METHODS: This is a retrospective study that was conducted in a tertiary care hospital with 550 beds in Ankara, Turkey, from January 2009 to July 2010. Thirty-three patients who had carbapenem-resistant Acinetobacter spp. infections and received tigecycline alone or in combination with other antibiotics for at least 3 days were included. RESULTS: The median age of the patients was 62 (18-87) years. All of the patients were diagnosed and treated in the ICU. Clinical responses were observed in 23 patients (69.7%). Ten patients (30%) had clinical failure. There was no significant difference between ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) in terms of clinical or microbiological outcome (p > 0.05). The microbiological response rate was 50%. Superinfection was detected in 13 patients (43.3%) and Pseudomonas aeruginosa was the most frequently isolated pathogen. The 30-day overall mortality rate and attributable mortality rates were 57.6 and 24.2%, respectively. The attributable mortality rate was higher in the group in which microbiological eradication was not provided. CONCLUSIONS: Although it is approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia, emerged resistance of Acinetobacter spp. and limited therapeutic options left physicians no choice but to use tigecycline for off-label indications.
Authors: J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; J Monterrubio-Villar; M Gili-Miner Journal: Crit Care Med Date: 1999-09 Impact factor: 7.598
Authors: Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan Journal: Emerg Infect Dis Date: 2007-01 Impact factor: 6.883
Authors: H Leblebicioglu; A N Yalcin; V D Rosenthal; I Koksal; F Sirmatel; S Unal; H Turgut; D Ozdemir; G Ersoz; C Uzun; S Ulusoy; S Esen; F Ulger; A Dilek; H Yilmaz; O Turhan; N Gunay; E Gumus; O Dursun; G Yýlmaz; S Kaya; H Ulusoy; M Cengiz; L Yilmaz; G Yildirim; A Topeli; S Sacar; H Sungurtekin; D Uğurcan; M F Geyik; A Şahin; S Erdogan; A Kaya; N Kuyucu; B Arda; F Bacakoglu Journal: Infection Date: 2013-01-26 Impact factor: 3.553
Authors: José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti Journal: Intensive Care Med Date: 2015-10-05 Impact factor: 17.440
Authors: J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow Journal: Infection Date: 2013-08-01 Impact factor: 3.553
Authors: K S Schwab; C Hahn-Ast; W J Heinz; U Germing; G Egerer; A Glasmacher; C Leyendecker; G Marklein; C M Nellessen; P Brossart; M von Lilienfeld-Toal Journal: Infection Date: 2013-08-25 Impact factor: 3.553